Mountain High Acquisitions Corp (OTCMKTS:MYHI) showing dropped of -0.47% and closed at $0.210, after gaining total volume of 475,356.00 shares. Its earnings per share (EPS) is -$0.02 and its beta value stands at 3.05 points and has total market capitalization of $11.89 million and a total of 58.05 million outstanding shares.
Mountain High Acquisitions Corp (MYHI) on May 12, 2015 announced that it has appointed Teri D. Vries to the positions of CEO and President, and to the Board of Directors of the Company. Teri D. Vries is a healthcare industry manager and business consultant with over 20 years of experience focused on strategy development, process improvement, change management, financial analysis and reporting, benchmarking, and business development with both large and mid-size organizations.
“We are very excited to have someone as qualified and highly regarded as Teri Vries join the Mountain High team as the Company’s new Chief Executive Officer and President,” stated Alan Smith, Director and former President of Mountain High. “Her significant business management and accounting qualifications, combined with her knowledge of nutraceutical distribution and marketing strategies, make her an ideal corporate leader as we move forward with our plans to develop the synergies between our two active subsidiaries, GreenLife BotaniX and Freedom Seed and Feed, in the CBD/hemp oil and industrial hemp sector.”
Prior to joining Mountain High, Vries was a Product Consultant to Highmark Inc., one of the leading health insurers in Pennsylvania, where she was project manager for initiatives valued at over $1 Billion over a seven year period. From 2003-05, Vries was a Senior Healthcare Consultant with McKesson Corporation, a Fortune Global 500 provider of health information technology, medical supplies, care management tools, and operator of the Health Mart network of over 2,500 independently owned pharmacies.
Teri Vries received a B.S. in Business Administration with a concentration in Accounting from the State University of New York at Oswego in 1990. She completed her graduate studies at Fordham University in New York City, earning a MBA with a concentration in Management in 1994.
Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 5.56% and closed at $1.90, with the total traded volume of 16,211.00 shares. During last trade its minimum price was $1.85 and it gained its highest price of $2.05 and has a total of 77.73 million outstanding shares.
On March 6, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.
At a meeting with the company’s Advisory Board on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.
The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.
Nemus Bioscience Inc (OTCMKTS:NMUS) increased 5.26% closed at $0.300 and traded with total volume of 277,596.00 shares, while the average trading remained 292,679.00 shares. During last trade its minimum price was $0.28 and it gained the highest price of $0.30. Its market capitalization was $7.38 million.
Nemus Bioscience Inc (NMUS) on March 22, 2017 announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA.
In vitro studies demonstrated that when using unique strategic cannabinoid-based cocktails, fractional-inhibitory concentration (FIC) levels demonstrating synergy between mixtures of individual cannabinoid-based components ranged from 0.06 to 0.28. FIC findings below 0.5 indicate significant killing potential of the mixture.
“This work highlights the importance of Nemus’ relationship with the University which has significant experience and intellectual capital related to cannabinoid chemistry and physiology, dating back to 1968,” stated Brian Murphy, M.D., C.E.O. and Chief Medical Officer of Nemus. “These unique botanically derived components establish an anti-infective platform which could potentially be expanded into other types of bacteria, as well as viruses, and fungi.”
Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research (NCNPR) at the University of Mississippi commented: “The University, in conjunction with Nemus, is looking to expand the anti-infective capabilities of this series of compounds. Historically, many types of anti-infective compounds are derived from plants so to have a series of cannabinoid-related compounds exhibit activity against this dangerous pathogen is in keeping with prior efforts of drug development. I believe that these compounds, in addition to the bacterial killing capability, could also offer benefits associated with anti-inflammatory and anti-fibrotic properties that could enhance healing, especially against an organism associated with skin and soft tissue infections.”